Pharmaceuticals company Glenmark Pharmaceuticals announced Q1FY26 results Consolidated revenue was Rs 32,644 million as against Rs 32,442 million, recording an increase of 0.6% YoY. EBITDA was Rs 5,805 million in Q1FY26, as compared to Rs 5,607 million in Q1FY25, with an EBITDA margin of 17.8%. Adjusted Profit After Tax (PAT) for Q1FY26 was at Rs 3,129 million, with an adjusted PAT margin of 9.6%. Glenn Saldanha, Chairman & Managing Director, Glenmark Pharmaceuticals, said: “In Q1FY26, our U.S. business delivered QoQ growth, driven by a combination of injectable and partnered products launches. Our Europe and Emerging markets businesses have recorded >25% CAGR and >10% CAGR respectively over the last three years, and we expect the region to deliver a double-digit growth from the second quarter onwards. The recent IGI-AbbVie global licensing agreement for ISB 2001 is a strong validation of our innovation capabilities. We remain confident in our strategy to drive growth across our markets, while advancing our branded, speciality, and innovative products to deliver long-term value for our stakeholders.” Result PDF
Conference Call with Max Healthcare Institute Management and Analysts on Q1FY26 Performance and Outlook. Listen to the full earnings transcript.